Understand the source comparison
Side effect profile comparison
This is where BRP shows its greatest potential advantage. Semaglutide commonly causes nausea, vomiting, diarrhea, and constipation. Up to 40% of patients experience gastrointestinal symptoms, particularly during dose escalation. Many patients cannot tolerate t
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- This is where BRP shows its greatest potential advantage.
- Semaglutide commonly causes nausea, vomiting, diarrhea, and constipation. Up to 40% of patients experience gastrointestinal symptoms, particularly during dose escalation. Many patients cannot tolerate the drug at effective doses. Weight loss from semaglutide also includes muscle and bone loss, accounting for up to 20% of total weight lost in some studies.
- BRP-treated animals showed no differences in anxiety-like behavior, water intake, locomotor activity, or fecal production compared to controls. No nausea or food aversion behaviors were observed. Most critically, weight loss came almost entirely from fat with no significant lean mass reduction.
- If these findings translate to humans, BRP could offer similar weight loss without the tolerability problems that limit GLP-1 drugs for many patients.